Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Tbilisi Pediatric Priva… | Healthcare Services | 35.0% | 92nd pct | 268 |
| Telavis Raionuli Saavad… | Healthcare Services | 5.0% | 35th pct | 268 |
| Neprologiis Ganvitarebi… | Healthcare Services | 4.0% | 32nd pct | 268 |
| Bomondi | Healthcare Services | -51.2% | 4th pct | 268 |
| Acharis A.r. Onkologiis… | Healthcare Services | — | no FY data | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 4 of 5 peers filed FY2024. Switch to FY2018 (5 of 5).
| Ratio — FY 2024 | Telavis Raionuli Saavad… | Bomondi | Tbilisi Pediatric Priva… | Neprologiis Ganvitarebi… | Acharis A.r. Onkologiis… |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 83.8% | 74.8% | 89.7% | 27.6% | — |
| EBITDA Margin | 5.0% | -51.2% | 35.0% | 4.0% | — |
| EBITDAR | 372 | -3,273 | 2,151 | 277 | — |
| EBITDAR Margin | 5.3% | -51.2% | 35.0% | 4.6% | — |
| EBIT Margin | -3.4% | -72.7% | 28.5% | 0.8% | — |
| Net Profit Margin | 6.1% | -106.4% | 30.4% | 0.8% | — |
| Operating Expense % of Sales | 78.8% | 126.0% | 54.7% | 23.6% | — |
| Returns | |||||
| Return on Assets (ROA) | 10.6% | -38.7% | 21.5% | 1.0% | — |
| Return on Equity (ROE) | 18.8% | N/A | 23.1% | 1.4% | — |
| ROIC [EBIT / Invested Capital] | |||||
| -7.6% |
| -46.6% |
| 22.9% |
| 1.5% |
| — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 31.0% | 94.1% | 0.0% | 0.0% | — |
| Debt-to-Equity | 0.55x | -2.55x | 0.00x | 0.00x | — |
| Debt-to-EBITDA | 3.58x | N/A | 0.00x | 0.00x | — |
| Equity-to-Assets | 56.6% | -36.9% | 93.0% | 70.5% | — |
| Net Debt | 884 | 16,443 | -445 | -62 | — |
| Cash & Equivalents | 357 | 73 | 445 | 62 | — |
| Total Debt | 1,240 | 16,515 | N/A | N/A | — |
| Liquidity & working capital | |||||
| Current Ratio | 3.08x | 0.78x | 2.86x | 1.48x | — |
| Quick Ratio | 3.08x | 0.77x | 2.51x | 1.48x | — |
| Cash Ratio | 0.72x | 0.01x | 0.73x | 0.05x | — |
| Total Current Assets | 1,530 | 5,850 | 1,752 | 1,883 | — |
| Total Current Liabilities | 497 | 7,514 | 613 | 1,270 | — |
| Inventory | N/A | 64 | 211 | N/A | — |
| Trade Receivables | 1,019 | 2,087 | 1,057 | 1,883 | — |
| Trade Payables | N/A | 1,399 | 380 | 1,207 | — |
| Net Working Capital | 1,033 | -1,664 | 1,138 | 613 | — |
| Net Working Capital % of Revenue | 14.8% | -26.0% | 18.5% | 10.3% | — |
| Trade Working Capital | 1,019 | 752 | 888 | 676 | — |
| Trade Working Capital % of Revenue | 14.6% | 11.8% | 14.5% | 11.3% | — |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | — |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | 25.04x | 2.99x | N/A | — |
| Days Inventory Outstanding (DIO) | N/A | 14.6 | 122.0 | N/A | — |
| Receivables Turnover | 6.86x | 3.06x | 5.81x | 3.16x | — |
| Days Sales Outstanding (DSO) | 53.2 | 119.2 | 62.8 | 115.4 | — |
| Payables Turnover | N/A | 1.15x | 1.66x | 3.57x | — |
| Days Payable Outstanding (DPO) | N/A | 316.9 | 219.6 | 102.2 | — |
| Cash Conversion Cycle | 53.2 days | -183.1 days | -34.8 days | 13.2 days | — |
| Asset Turnover | 1.75x | 0.36x | 0.71x | 1.19x | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | 112 | -128 | -511 | 125 | — |
| Free Cash Flow (OCF − Capex proxy) | 112 | -128 | -554 | 3 | — |
| Cash Conversion (OCF / EBITDA) | 32.5% | N/A | -23.8% | 52.0% | — |
| Dividends Declared | N/A | 0 | 3,399 | N/A | — |
| Dividend Payout Ratio | N/A | N/A | 181.8% | N/A | — |